Discover open access scientific publications

Search, annotate, share and cite publications

Publications by David Inwards

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy

American Journal of Hematology

Hematology

2017

English

Related publications

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica

Hematology

2015

English

A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma

British Journal of Haematology

Hematology

2015

English

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

Hematological Oncology

English

A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma

English

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Hematological Oncology

English

Phase 2 Study of BACOPP (Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone) in Older Patients With Hodgkin Lymphoma: A Report From the German Hodgkin Study Group (GHSG)

English

Time and Motion Study for Rituximab Sc vs Iv in Colombian Patients With Non-Hodgkin Lymphoma

English

Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by David Inwards

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy

Related publications

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Indolent Non-Hodgkin's Lymphoma

A Phase Ii Trial of Rituximab/Lenalidomide Followed by Lenalidomide Maintenance in Untreated and Relapsed Indolent Lymphoma: Long Term Follow Up and Correlative Analysis

A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

A PHASE 2 CLINICAL TRIAL OF RITUXIMAB AND Β-Glucan PGG IN RELAPSED/REFRACTORY INDOLENT B-Cell NON-HODGKIN LYMPHOMA

Phase 2 Study of BACOPP (Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone) in Older Patients With Hodgkin Lymphoma: A Report From the German Hodgkin Study Group (GHSG)

Time and Motion Study for Rituximab Sc vs Iv in Colombian Patients With Non-Hodgkin Lymphoma

Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience